

ongoing trials - trial from www.clinicaltrials.gov

Clinical trial of comparison between use of intravenous aminoglycosides versus intravenous and nebulize aminoglycosides in cystic fibrosis patients - Recruiting

Code:
IRCT20120415009475N10

Year: 2021 **Date:** June 29, 2021

Author:

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment

Participants

Cystic Fibrosis (CF) - 18 Years and older (Adult, Older Adult)

Interventions

Drug: Galicafort|Drug: Placebo|Drug: Navocafort|Drug: ABBV-119

Outcome measures

Absolute Change From Baseline in ppFEV1|Absolute Change From Baseline in Sweat Chloride (SwCl)|Absolute Change From Baseline in Forced Vital Capacity [FVC]|Absolute Change From Baseline in Forced Expiratory Flow at Mid-Lung Capacity [FEF25-75]|Relative Changes From Baseline in ppFEV1|Relative Changes From Baseline in FVC|Relative Changes From Baseline in FEF25-75|Absolute Change in CF Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline

<http://en.irct.ir/trial/55963>

Keywords

Adult; Aminophenols; CFTR Modulators; Genetic Predisposition to Disease; pharmacological_intervention; Galicafort; Navocafort; ABBV119;